Compound traditional Chinese medicine composition and application thereof to resistance to prostate cancer

Abstract

The invention discloses a compound traditional Chinese medicine composition and application thereof to resistance to prostate cancer. The compound traditional Chinese medicine composition is mainly prepared from the following traditional Chinese medicine raw materials in parts by weight: 4-12 parts of bark of ailanthus altissima, 12-30 parts of spreading hedyotis herb, 3-15 arts of curcuma zedoary, 15-30 parts of salvia miltiorrhiza, 5-15 parts of selfheal and 4-12 parts of liquorice. According to the compound traditional Chinese medicine composition having a prostate cancer-resistant effect, a raw material composition formula is selected according to the traditional Chinese medicine theory and pathogenesis of prostate cancer, all components are scientific and reasonable in ratio, and pharmacological experiment and preclinical experiment results show that the compound traditional Chinese medicine composition provided by the invention has a good prostate cancer-resistant effect, not only can obviously restrain the proliferation and growth of the prostate cancer, but also can restrain migration, invasion and transfer of the prostate cancer, obviously improve the survival quality of tumor-bearing mice, and improve all immune indexes of the tumor-bearing mice, is convenient and rapid in administration route, has no obvious adverse effects, can be developed to be a new-generation prostate cancer-resistant drug and has high potential of becoming a good prostate cancer treatment prescription.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a traditional Chinese medicine compound composition and its application in preparing anti-prostate cancer. Background technique [0002] Prostate cancer (PCa), as the most common malignant tumor of the male reproductive system, is a disease that occurs frequently in elderly men, and its incidence increases with age. The incidence of prostate cancer is unevenly distributed around the world. Every year, there are more than 900,000 new cases worldwide, of which more than 260,000 cases die due to the progression of prostate cancer. The incidence of prostate cancer in European and American countries is significantly higher than that in Asia and Africa. In the United States, prostate cancer accounts for the first incidence rate and the second death rate of male tumors in the United States. In my country, the incidence of prostate cancer has increased by 70% compared with the past, ...

AI Technical Summary

Problems solved by technology

The latest drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of CRPC include Abiraterone (Abiraterone) and MDV3100 (Enzalutamide). The former inhibits the synthesis of androgen, and the latter is an antagonist of the androgen receptor. Both of these drugs target the androgen receptor signaling pathway, and have achieved significant curative effects in the treatment of castration-resistant prostate cancer. However, after the above-mentioned endocrine therapy and androgen receptor-targeted drug treatment, the patient still develops drugs. Resistance, the treatment effect is very limited, and the cost is expensive, and the patient's economic ability is poor

In addition, the side effects caused by radiotherapy and chemotherapy are also the bottleneck of clinical treatment.

Images